- Trastuzumab-emtansine Too Costly for Use on the NHS England
- ESMO Asia 2015 Press Release: Afatinib a Better Choice for EGFR-Mutated Lung Cancer in First-Line
- ESMO Asia 2015 News: Durvalumab, Tremelimumab Duo Promising in Advanced NSCLC
- ESMO Asia 2015 Press Release: Asian Women with Endocrine-Resistant Breast Cancer Benefit from Combination Therapy
- ESMO Asia 2015 News: Endocrine Therapy in Premenopausal Women: Selecting Patients, Treatments and Durations
- ESMO Asia 2015 Press Release: Immunotherapy and targeted therapy provide new options for difficult-to-treat head and neck cancer
- No Benefit From Adjuvant Chemotherapy in High Risk Premenopausal Luminal A Breast Cancer Patients
- The Impact of Adjuvant Denosumab on Disease-free Survival in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
- FDA Approves Alectinib for the Treatment of Advanced ALK-positive NSCLC
- Midostaurin Prolongs Survival in Newly Diagnosed Acute Myeloid Leukaemia Patients With FLT3 Mutations
- FDA Approves Elotuzumab for the Treatment of Multiple Myeloma
- Lung Adenocarcinoma With HER2 Mutations
- FDA Approves Nivolumab as a Single Agent for Previously Untreated BRAF Wild-Type Advanced Melanoma
- FDA Approves Necitumumab to Treat Advanced Squamous NSCLC
- European Medicines Agency Recommends Granting a Marketing Authorisation for Pemetrexed Accord and Pemetrexed Actavis
- FDA Approves Ixazomib, New Oral Proteasome Inhibitor for Treatment of Multiple Myeloma
- FDA Approves Nivolumab for the Treatment of Advanced Renal Cell Cancer
- European Medicines Agency Recommends Granting a Marketing Authorisation for Asparaginase and Pegaspargase
- Dabrafenib Produces Rapid Shrinkage of Recurrent, BRAF-mutant Papillary Craniopharyngioma
- FDA Approves Osimertinib to Treat Patients With EGFR T790M Positive Advanced NSCLC After Progression to Other EGFR Tyrosine Kinase Inhibitors
- FDA Approves Cobimetinib as Part of Combination Treatment for Advanced Melanoma
- EMA Recommends Approval of Ciambra, Pemetrexed Hospira and Pemetrexed Medac
- FDA Approves Liposomal Irinotecan for Advanced Pancreatic Cancer
- FDA Approves Trabectedin for Certain Types of Advanced Soft Tissue Sarcoma
- EMA Adopts a Positive Opinion Recommending to Extend Therapeutic Indications for Crizotinib